<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757287</url>
  </required_header>
  <id_info>
    <org_study_id>SMD-DES-2016-01</org_study_id>
    <nct_id>NCT02757287</nct_id>
  </id_info>
  <brief_title>Desogestrel (DSG) and Corifollitropin(FSH-CTP) Alfa for Ovarian Stimulation in Donors</brief_title>
  <official_title>Desogestrel and Corifollitropin Treatment for Ovarian Stimulation in Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Universitari Dexeus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Dexeus Salud de la Mujer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Universitari Dexeus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, controlled ovarian stimulation (COS) in oocyte donors is performed by daily
      injections of gonadotropins( recombinant FSH) plus a GnRH Antagonist usually form 5th-6th
      stimulation day until ovulation induction with a bolus of another injection of a
      gonadotropin-releasing hormone (GnRH) Agonist. Injections of the GnRH Antagonist avoid
      untimely luteinizing hormone (LH) surge and spontaneous ovulation prior to follicular
      aspiration. There is a preparation of long-acting recombinant follicle stimulating hormone
      (rFSH= (corifollitropin alfa (FSH-CTP), Elonva®, MSD), that allows that a single subcutaneous
      injection substitutes the first 7 days of daily gonadotropin injections. On the other hand, a
      contraceptive oral progesterone only( Desogestrel, DSG) is available for contraception,
      avoiding the LH surge. It has been described the usefulness of orally administered
      medroxyprogesterone acetate, 10 mg to inhibit the endogenous LH surge in IVF patients during
      COS.

      In donors, by administering a single injection of FSH-CTP and oral desogestrel since the
      first menstruation day, the total number of injections administered is reduced and less
      discomfort is experienced without adverse impact on ovarian response. No description of the
      hormonal and ovarian response under this protocol has been published
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  oral desogestrel since the first menstruation day,

        -  a single injection of FSH-CTP on the 7th menstrual cycle day

        -  routine monitoring of ovarian response with transvaginal ultrasound every second day
           until pre-ovulatory bolus of GnRH

        -  Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH
           and the day after the bolus ( estradiol, FSH, Progesterone, LH)

        -  Quality of Life questionnaire the day after the bolus
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Lack of financial support
  </why_stopped>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total dose of gonadotrophins</measure>
    <time_frame>At the end of the stimulation treatment period (5 or 7 days after begining of treatment)</time_frame>
    <description>Total Consume of gonadotrophins</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma LH</measure>
    <time_frame>Day of GnrH bolus</time_frame>
    <description>Level of LH in plasma (mIU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of mature oocytes</measure>
    <time_frame>Day of oocyte recovery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>FSH-CTP + DESOGESTREL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of FSH-CTP and oral desogestrel since the first menstruation day, until bolus of GnRH agonist to follicular maturation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FSH-CTP + DESOGESTREL</intervention_name>
    <description>Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)
- Quality of Life questionnaire the day after the bolus</description>
    <arm_group_label>FSH-CTP + DESOGESTREL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Population: donors (18-35 ) from candidates of Donor program

          -  Fulfilling inclusión medical and legal criteria (RD -Ley de transposición de la
             normativa europea a la legislación española 9/2014)

          -  Who had had undergone previously convencional COS (controlled ovarian stimulation)
             with FSH-CTP and daily antagonist injections

          -  Given signed consent form.

        Exclusion Criteria:

          -  Previous low response to COS

          -  Previous ovarian hyperstimulation syndrome.

          -  Ovarian cysts.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Quiron Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.dexeus.com/</url>
  </link>
  <reference>
    <citation>Martínez F, Boada M, Coroleu B, Clua E, Parera N, Rodríguez I, Barri PN. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH. Hum Reprod. 2006 Aug;21(8):2121-5. Epub 2006 Apr 21.</citation>
    <PMID>16632462</PMID>
  </reference>
  <reference>
    <citation>Martínez F, Clua E, Santmartí P, Boada M, Rodriguez I, Coroleu B. Randomized, comparative pilot study of pituitary suppression with depot leuprorelin versus cetrorelix acetate 3 mg in gonadotropin stimulation protocols for oocyte donors. Fertil Steril. 2010 Nov;94(6):2433-6. doi: 10.1016/j.fertnstert.2010.02.059. Epub 2010 Apr 28.</citation>
    <PMID>20430379</PMID>
  </reference>
  <reference>
    <citation>Requena A, Cruz M, Collado D, Izquierdo A, Ballesteros A, Muñoz M, García-Velasco JA. Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin α. Reprod Biomed Online. 2013 Mar;26(3):253-9. doi: 10.1016/j.rbmo.2012.11.015. Epub 2012 Dec 5.</citation>
    <PMID>23352098</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Universitari Dexeus</investigator_affiliation>
    <investigator_full_name>Dr. Francisca Martínez</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Ovarian stimulation</keyword>
  <keyword>LH inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

